Drug Profile
Research programme: trioxaquines - PALUMED/sanofi-aventis
Alternative Names: DU1302; PA 1103; SAR 116242Latest Information Update: 08 Jul 2016
Price :
$50
*
At a glance
- Originator PALUMED; sanofi-aventis
- Developer PALUMED; Sanofi
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malaria